Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation
This study was performed to analyze the influence of either aspirin, ticlopidine, or their combination on platelet activation and aggregation parameters after stent implantation. Sixty-one patients with successful implantation of a single Palmaz-Schatz stent in a native coronary artery were randomly...
Gespeichert in:
| Veröffentlicht in: | Circulation (New York, N.Y.) N.Y.), 1998-03, Vol.97 (11), p.1046-1052 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1052 |
|---|---|
| container_issue | 11 |
| container_start_page | 1046 |
| container_title | Circulation (New York, N.Y.) |
| container_volume | 97 |
| creator | RUPPRECHT, H. J DARIUS, H BORKOWSKI, U VOIGTLÄNDER, T NOWAK, B GENTH, S MEYER, J |
| description | This study was performed to analyze the influence of either aspirin, ticlopidine, or their combination on platelet activation and aggregation parameters after stent implantation.
Sixty-one patients with successful implantation of a single Palmaz-Schatz stent in a native coronary artery were randomly assigned to either group A (aspirin 300 mg/d+ticlopidine 2X250 mg/d), group B (ticlopidine 2X250 mg/d), or group C (aspirin 300 mg/d). Platelet activation was evaluated on days 1, 7, and 14 by flow cytometry measurement of expression of CD62p (p-selectin) and the binding of fibrinogen to the platelet surface glycoprotein IIb/IIIa receptor. Platelet aggregation was induced by addition of ADP or collagen. Differences between treatment groups were compared by ANOVA. Between days 1 and 14, we observed a significant decrease in collagen-induced platelet aggregation in group A (62.2+/-2.5% versus 36.9+/-3.1%), whereas an increase was seen in group B (58.3+/-2.5% versus 67.7+/-3.2%) and no change was seen in group C (P |
| doi_str_mv | 10.1161/01.CIR.97.11.1046 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79763300</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79763300</sourcerecordid><originalsourceid>FETCH-LOGICAL-c437t-b4b05f30caba6bc046c88f7a57657d321711752edaeb46488bd5120aa2620e0b3</originalsourceid><addsrcrecordid>eNpdkU9vFSEUxYnR1Gf1A7gwIca46jy5MMCbZfPinyZNTIyuCTCXSDMDI_AWfntp-9KFK3I4v3ty4RDyFtgeQMEnBvvjzY_9pLvcAxvVM7IDycdhlGJ6TnaMsWnQgvOX5FWtd10qoeUFuZikAC5hR-Ixr5stseZEc6A2tbgttuGCjWII6Ft9uK9bLDFd0Rb9krc4x4RXNBfafmMs1OfVxWRb7Ck2NCy0NkyNxrWHpfZgvCYvgl0qvjmfl-TXl88_j9-G2-9fb47Xt4MfhW6DGx2TQTBvnVXO9zf5wyFoK7WSehYcNICWHGeLblTj4eBmCZxZyxVnyJy4JB8fc7eS_5ywNrPG6nHpi2A-VaMnrYRgrIPv_wPv8qmkvpvhwJWUoFSH4BHyJddaMJitxNWWvwaYue_AMDC9AzPpLs19B33m3Tn45FacnybOn979D2ffVm-XUGzysT5hHKZpZFr8A5Z6j2c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212655166</pqid></control><display><type>article</type><title>Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>RUPPRECHT, H. J ; DARIUS, H ; BORKOWSKI, U ; VOIGTLÄNDER, T ; NOWAK, B ; GENTH, S ; MEYER, J</creator><creatorcontrib>RUPPRECHT, H. J ; DARIUS, H ; BORKOWSKI, U ; VOIGTLÄNDER, T ; NOWAK, B ; GENTH, S ; MEYER, J</creatorcontrib><description>This study was performed to analyze the influence of either aspirin, ticlopidine, or their combination on platelet activation and aggregation parameters after stent implantation.
Sixty-one patients with successful implantation of a single Palmaz-Schatz stent in a native coronary artery were randomly assigned to either group A (aspirin 300 mg/d+ticlopidine 2X250 mg/d), group B (ticlopidine 2X250 mg/d), or group C (aspirin 300 mg/d). Platelet activation was evaluated on days 1, 7, and 14 by flow cytometry measurement of expression of CD62p (p-selectin) and the binding of fibrinogen to the platelet surface glycoprotein IIb/IIIa receptor. Platelet aggregation was induced by addition of ADP or collagen. Differences between treatment groups were compared by ANOVA. Between days 1 and 14, we observed a significant decrease in collagen-induced platelet aggregation in group A (62.2+/-2.5% versus 36.9+/-3.1%), whereas an increase was seen in group B (58.3+/-2.5% versus 67.7+/-3.2%) and no change was seen in group C (P<.0001). The ADP-induced aggregation declined significantly in group A (74.7+/-1.4% versus 55.3+/-2.6%), whereas a delayed reduction was seen in group B (72.0+/-3.0% versus 52.6+/-4.2%) and no change was seen in group C (P=.0017). The CD62p expression declined significantly in groups A (68.2+/-2.7% versus 41.3+/-2.7%) and B (64.8+/-2.9% versus 39.3+/-3.5%) but not in group C (P<.0001). Moreover, the fibrinogen binding decreased significantly in group A (61.0+/-4.3% versus 36.3+/-4.2%) and with delay in group B (58.3+/-2.2% versus 39.4+/-3.0%), whereas no alterations were seen in group C (P=.012).
Our results demonstrate synergistic and accelerated platelet inhibitory effects of ticlopidine plus aspirin in patients after stent implantation compared with a monotherapy with either ticlopidine or aspirin alone.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/01.CIR.97.11.1046</identifier><identifier>PMID: 9531251</identifier><identifier>CODEN: CIRCAZ</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Angioplasty, Balloon, Coronary ; Aspirin - pharmacology ; Aspirin - therapeutic use ; Biological and medical sciences ; Blood. Blood coagulation. Reticuloendothelial system ; Coronary Disease - therapy ; Drug Therapy, Combination ; Fibrinogen - metabolism ; Humans ; Medical sciences ; P-Selectin - analysis ; Pharmacology. Drug treatments ; Platelet Aggregation - drug effects ; Platelet Aggregation Inhibitors - pharmacology ; Platelet Aggregation Inhibitors - therapeutic use ; Platelet Glycoprotein GPIIb-IIIa Complex - metabolism ; Stents ; Ticlopidine - pharmacology ; Ticlopidine - therapeutic use ; Time Factors</subject><ispartof>Circulation (New York, N.Y.), 1998-03, Vol.97 (11), p.1046-1052</ispartof><rights>1998 INIST-CNRS</rights><rights>Copyright American Heart Association, Inc. Mar 24, 1998</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c437t-b4b05f30caba6bc046c88f7a57657d321711752edaeb46488bd5120aa2620e0b3</citedby><cites>FETCH-LOGICAL-c437t-b4b05f30caba6bc046c88f7a57657d321711752edaeb46488bd5120aa2620e0b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3674,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2199407$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9531251$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>RUPPRECHT, H. J</creatorcontrib><creatorcontrib>DARIUS, H</creatorcontrib><creatorcontrib>BORKOWSKI, U</creatorcontrib><creatorcontrib>VOIGTLÄNDER, T</creatorcontrib><creatorcontrib>NOWAK, B</creatorcontrib><creatorcontrib>GENTH, S</creatorcontrib><creatorcontrib>MEYER, J</creatorcontrib><title>Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description>This study was performed to analyze the influence of either aspirin, ticlopidine, or their combination on platelet activation and aggregation parameters after stent implantation.
Sixty-one patients with successful implantation of a single Palmaz-Schatz stent in a native coronary artery were randomly assigned to either group A (aspirin 300 mg/d+ticlopidine 2X250 mg/d), group B (ticlopidine 2X250 mg/d), or group C (aspirin 300 mg/d). Platelet activation was evaluated on days 1, 7, and 14 by flow cytometry measurement of expression of CD62p (p-selectin) and the binding of fibrinogen to the platelet surface glycoprotein IIb/IIIa receptor. Platelet aggregation was induced by addition of ADP or collagen. Differences between treatment groups were compared by ANOVA. Between days 1 and 14, we observed a significant decrease in collagen-induced platelet aggregation in group A (62.2+/-2.5% versus 36.9+/-3.1%), whereas an increase was seen in group B (58.3+/-2.5% versus 67.7+/-3.2%) and no change was seen in group C (P<.0001). The ADP-induced aggregation declined significantly in group A (74.7+/-1.4% versus 55.3+/-2.6%), whereas a delayed reduction was seen in group B (72.0+/-3.0% versus 52.6+/-4.2%) and no change was seen in group C (P=.0017). The CD62p expression declined significantly in groups A (68.2+/-2.7% versus 41.3+/-2.7%) and B (64.8+/-2.9% versus 39.3+/-3.5%) but not in group C (P<.0001). Moreover, the fibrinogen binding decreased significantly in group A (61.0+/-4.3% versus 36.3+/-4.2%) and with delay in group B (58.3+/-2.2% versus 39.4+/-3.0%), whereas no alterations were seen in group C (P=.012).
Our results demonstrate synergistic and accelerated platelet inhibitory effects of ticlopidine plus aspirin in patients after stent implantation compared with a monotherapy with either ticlopidine or aspirin alone.</description><subject>Angioplasty, Balloon, Coronary</subject><subject>Aspirin - pharmacology</subject><subject>Aspirin - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Coronary Disease - therapy</subject><subject>Drug Therapy, Combination</subject><subject>Fibrinogen - metabolism</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>P-Selectin - analysis</subject><subject>Pharmacology. Drug treatments</subject><subject>Platelet Aggregation - drug effects</subject><subject>Platelet Aggregation Inhibitors - pharmacology</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Platelet Glycoprotein GPIIb-IIIa Complex - metabolism</subject><subject>Stents</subject><subject>Ticlopidine - pharmacology</subject><subject>Ticlopidine - therapeutic use</subject><subject>Time Factors</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU9vFSEUxYnR1Gf1A7gwIca46jy5MMCbZfPinyZNTIyuCTCXSDMDI_AWfntp-9KFK3I4v3ty4RDyFtgeQMEnBvvjzY_9pLvcAxvVM7IDycdhlGJ6TnaMsWnQgvOX5FWtd10qoeUFuZikAC5hR-Ixr5stseZEc6A2tbgttuGCjWII6Ft9uK9bLDFd0Rb9krc4x4RXNBfafmMs1OfVxWRb7Ck2NCy0NkyNxrWHpfZgvCYvgl0qvjmfl-TXl88_j9-G2-9fb47Xt4MfhW6DGx2TQTBvnVXO9zf5wyFoK7WSehYcNICWHGeLblTj4eBmCZxZyxVnyJy4JB8fc7eS_5ywNrPG6nHpi2A-VaMnrYRgrIPv_wPv8qmkvpvhwJWUoFSH4BHyJddaMJitxNWWvwaYue_AMDC9AzPpLs19B33m3Tn45FacnybOn979D2ffVm-XUGzysT5hHKZpZFr8A5Z6j2c</recordid><startdate>19980324</startdate><enddate>19980324</enddate><creator>RUPPRECHT, H. J</creator><creator>DARIUS, H</creator><creator>BORKOWSKI, U</creator><creator>VOIGTLÄNDER, T</creator><creator>NOWAK, B</creator><creator>GENTH, S</creator><creator>MEYER, J</creator><general>Lippincott Williams & Wilkins</general><general>American Heart Association, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>U9A</scope><scope>7X8</scope></search><sort><creationdate>19980324</creationdate><title>Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation</title><author>RUPPRECHT, H. J ; DARIUS, H ; BORKOWSKI, U ; VOIGTLÄNDER, T ; NOWAK, B ; GENTH, S ; MEYER, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c437t-b4b05f30caba6bc046c88f7a57657d321711752edaeb46488bd5120aa2620e0b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Angioplasty, Balloon, Coronary</topic><topic>Aspirin - pharmacology</topic><topic>Aspirin - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Coronary Disease - therapy</topic><topic>Drug Therapy, Combination</topic><topic>Fibrinogen - metabolism</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>P-Selectin - analysis</topic><topic>Pharmacology. Drug treatments</topic><topic>Platelet Aggregation - drug effects</topic><topic>Platelet Aggregation Inhibitors - pharmacology</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Platelet Glycoprotein GPIIb-IIIa Complex - metabolism</topic><topic>Stents</topic><topic>Ticlopidine - pharmacology</topic><topic>Ticlopidine - therapeutic use</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>RUPPRECHT, H. J</creatorcontrib><creatorcontrib>DARIUS, H</creatorcontrib><creatorcontrib>BORKOWSKI, U</creatorcontrib><creatorcontrib>VOIGTLÄNDER, T</creatorcontrib><creatorcontrib>NOWAK, B</creatorcontrib><creatorcontrib>GENTH, S</creatorcontrib><creatorcontrib>MEYER, J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>RUPPRECHT, H. J</au><au>DARIUS, H</au><au>BORKOWSKI, U</au><au>VOIGTLÄNDER, T</au><au>NOWAK, B</au><au>GENTH, S</au><au>MEYER, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>1998-03-24</date><risdate>1998</risdate><volume>97</volume><issue>11</issue><spage>1046</spage><epage>1052</epage><pages>1046-1052</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><coden>CIRCAZ</coden><abstract>This study was performed to analyze the influence of either aspirin, ticlopidine, or their combination on platelet activation and aggregation parameters after stent implantation.
Sixty-one patients with successful implantation of a single Palmaz-Schatz stent in a native coronary artery were randomly assigned to either group A (aspirin 300 mg/d+ticlopidine 2X250 mg/d), group B (ticlopidine 2X250 mg/d), or group C (aspirin 300 mg/d). Platelet activation was evaluated on days 1, 7, and 14 by flow cytometry measurement of expression of CD62p (p-selectin) and the binding of fibrinogen to the platelet surface glycoprotein IIb/IIIa receptor. Platelet aggregation was induced by addition of ADP or collagen. Differences between treatment groups were compared by ANOVA. Between days 1 and 14, we observed a significant decrease in collagen-induced platelet aggregation in group A (62.2+/-2.5% versus 36.9+/-3.1%), whereas an increase was seen in group B (58.3+/-2.5% versus 67.7+/-3.2%) and no change was seen in group C (P<.0001). The ADP-induced aggregation declined significantly in group A (74.7+/-1.4% versus 55.3+/-2.6%), whereas a delayed reduction was seen in group B (72.0+/-3.0% versus 52.6+/-4.2%) and no change was seen in group C (P=.0017). The CD62p expression declined significantly in groups A (68.2+/-2.7% versus 41.3+/-2.7%) and B (64.8+/-2.9% versus 39.3+/-3.5%) but not in group C (P<.0001). Moreover, the fibrinogen binding decreased significantly in group A (61.0+/-4.3% versus 36.3+/-4.2%) and with delay in group B (58.3+/-2.2% versus 39.4+/-3.0%), whereas no alterations were seen in group C (P=.012).
Our results demonstrate synergistic and accelerated platelet inhibitory effects of ticlopidine plus aspirin in patients after stent implantation compared with a monotherapy with either ticlopidine or aspirin alone.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>9531251</pmid><doi>10.1161/01.CIR.97.11.1046</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-7322 |
| ispartof | Circulation (New York, N.Y.), 1998-03, Vol.97 (11), p.1046-1052 |
| issn | 0009-7322 1524-4539 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79763300 |
| source | MEDLINE; American Heart Association Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete |
| subjects | Angioplasty, Balloon, Coronary Aspirin - pharmacology Aspirin - therapeutic use Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Coronary Disease - therapy Drug Therapy, Combination Fibrinogen - metabolism Humans Medical sciences P-Selectin - analysis Pharmacology. Drug treatments Platelet Aggregation - drug effects Platelet Aggregation Inhibitors - pharmacology Platelet Aggregation Inhibitors - therapeutic use Platelet Glycoprotein GPIIb-IIIa Complex - metabolism Stents Ticlopidine - pharmacology Ticlopidine - therapeutic use Time Factors |
| title | Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T15%3A22%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20antiplatelet%20effects%20of%20aspirin,%20ticlopidine,%20or%20their%20combination%20after%20stent%20implantation&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=RUPPRECHT,%20H.%20J&rft.date=1998-03-24&rft.volume=97&rft.issue=11&rft.spage=1046&rft.epage=1052&rft.pages=1046-1052&rft.issn=0009-7322&rft.eissn=1524-4539&rft.coden=CIRCAZ&rft_id=info:doi/10.1161/01.CIR.97.11.1046&rft_dat=%3Cproquest_cross%3E79763300%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212655166&rft_id=info:pmid/9531251&rfr_iscdi=true |